share_log

復宏漢霖(02696.HK)旗下藥品HLX02營銷授權申請獲歐盟委員會批准

The license application for HLX02 license of 02696.HK products is approved by the license Committee.

即市頭條 ·  Jul 29, 2020 12:09

Lin Honglin-B (02696.HK) announced that its business partner Accord Healthcare S.L.U. The submitted HLX02 license application shall be approved by the PRC. After approval, HLX02 may be listed centrally in all member countries of the League, as well as in Iceland, Liechtenstein and Norway.

HLX02 is a single anti-biological analogue independently developed by the company in accordance with the biological guidelines of China and the League. It is used for the treatment of early HER2 breast cancer, HER2 metastatic breast cancer, and untreated HER2 metastatic gastric cancer or gastric / esophageal junctional adenocarcinoma. (jc/w) ~

Aswick has a new economy.

Web address: www.aastocks.com

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment